For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications . The study was ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Mounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of ...

Amazon says the company will join other partners including United Parcel Service and the U.S. Postal Service that regularly work alongside Amazon's last-mile delivery network. The private-equity ...

EUROPEAN shares started the week on a positive note on Monday after the United States and China agreed to temporarily slash ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...

One of the major concerns among aging men nowadays is the accumulation of excess belly fat. It’s not only unattractive and ...